Matinas BioPharma (NYSEAMERICAN:MTNB – Get Rating) issued its quarterly earnings data on Thursday. The company reported ($0.03) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.03), Fidelity Earnings reports.

Matinas BioPharma Price Performance

NYSEAMERICAN:MTNB opened at $0.84 on Friday. Matinas BioPharma has a 1 year low of $0.49 and a 1 year high of $1.61. The stock has a market capitalization of $182.67 million, a price-to-earnings ratio of -7.02 and a beta of 1.96.

Institutional Trading of Matinas BioPharma

A number of institutional investors have recently modified their holdings of MTNB. Atria Wealth Solutions Inc. acquired a new position in Matinas BioPharma during the first quarter worth approximately $32,000. Private Advisor Group LLC increased its position in Matinas BioPharma by 59.7% during the first quarter. Private Advisor Group LLC now owns 239,494 shares of the company's stock worth $192,000 after buying an additional 89,553 shares during the last quarter. State Street Corp increased its position in Matinas BioPharma by 8.0% during the first quarter. State Street Corp now owns 712,471 shares of the company's stock worth $573,000 after buying an additional 52,897 shares during the last quarter. Finally, BlackRock Inc. increased its position in Matinas BioPharma by 0.7% during the first quarter. BlackRock Inc. now owns 4,325,053 shares of the company's stock worth $3,479,000 after buying an additional 29,643 shares during the last quarter. 12.40% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Matinas BioPharma Company Profile

(Get Rating)

Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.

Featured Articles

• Get a free copy of the StockNews.com research report on Matinas BioPharma (MTNB)
• MarketBeat: Week in Review 8/8 – 8/12
• 2 Important Retail Stock Battles to Watch
• What Is WallStreetBets and What Stocks Are They Targeting?
• Institutions And Analysts Propel Jack In The Box Higher
• Can You Guess Which EV Stock Is Beating Tesla ?

Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.